Jeannie Lee Acquires 802 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jeannie Lee purchased 802 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of GBX 5,069 per share, with a total value of £40,653.38.

GSK Stock Up 1.8%

Shares of GSK stock traded up GBX 35.50 on Tuesday, reaching GBX 1,960. 27,888,139 shares of the company were exchanged, compared to its average volume of 8,764,782. The company has a market cap of £78.60 billion, a price-to-earnings ratio of 13.79, a PEG ratio of 1.24 and a beta of 0.29. The company has a 50-day moving average of GBX 1,955.63 and a 200-day moving average of GBX 1,966.35. The company has a debt-to-equity ratio of 106.74, a current ratio of 0.79 and a quick ratio of 0.73. GSK plc has a one year low of GBX 1,288.61 and a one year high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The business had revenue of GBX 762.90 billion for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Analysts anticipate that GSK plc will post 175.980975 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on GSK shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,900 price target on shares of GSK in a research note on Monday, June 8th. Berenberg Bank reaffirmed a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Shore Capital Group reiterated a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Citigroup decreased their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Thursday, May 28th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.